Nuvation Bio is trading at $6.41 (4.1% up), rebounding from recent weakness and moving broadly in line with today’s strong risk-on mood across U.S. equities.
- The move appears driven by upbeat macro data and easing geopolitical stress rather than any new company-specific catalysts.
- No fresh earnings, FDA updates, or analyst actions have been reported for the company during this session.
- The stock is benefiting from a strong rally in major indices, which is lifting sentiment across the broader market.